Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment

Ye, Jiaen; Feng, Jia‐Xun; Jiang, Deguo; Lin, Xiaodong; Chen, Guangdong; Zhang, Wei; Shan, Peiwei; Zhang, Li; Zhuo, Chuanjun

doi:10.3389/fnins.2019.00355

Cited by 9 publications

(11 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have, thus far, discussed the role of DA in various diseases from a systems and neural circuit perspective. However, as further evidence, DA-related genes are implicated as molecular modulators or risk factors for neuropsychiatric diseases such as schizophrenia and addiction [221][222][223][224]. Many of these implicated genes are involved in DA recycling and thus DA homeostasis.…”

Section: Dopamine System Genes and Neuropsychiatric Diseasementioning

confidence: 98%

“…Many of these implicated genes are involved in DA recycling and thus DA homeostasis. Genetic polymorphisms of a dopamine transporter (DAT), a primary enzyme responsible for recycling DA, impact treatment resistance susceptibility and working memory function in patients with schizophrenia [222,225,226]. Furthermore, DAT polymorphisms have been associated with behavioral deficits in anxiety and attention [227,228].…”

Section: Dopamine System Genes and Neuropsychiatric Diseasementioning

confidence: 99%

See 1 more Smart Citation

Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease

Chen,

Kim

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Dopamine (DA) is a behaviorally and clinically diverse neuromodulator that controls CNS function. DA plays major roles in many behaviors including locomotion, learning, habit formation, perception, and memory processing. Reflecting this, DA dysregulation produces a wide variety of cognitive symptoms seen in neuropsychiatric diseases such as Parkinson’s, Schizophrenia, addiction, and Alzheimer’s disease. Here, we review recent advances in the DA systems neuroscience field and explore the advancing hypothesis that DA’s behavioral function is linked to disease deficits in a neural circuit-dependent manner. We survey different brain areas including the basal ganglia’s dorsomedial/dorsolateral striatum, the ventral striatum, the auditory striatum, and the hippocampus in rodent models. Each of these regions have different reported functions and, correspondingly, DA’s reflecting role in each of these regions also has support for being different. We then focus on DA dysregulation states in Parkinson’s disease, addiction, and Alzheimer’s Disease, emphasizing how these afflictions are linked to different DA pathways. We draw upon ideas such as selective vulnerability and region-dependent physiology. These bodies of work suggest that different channels of DA may be dysregulated in different sets of disease. While these are great advances, the fine and definitive segregation of such pathways in behavior and disease remains to be seen. Future studies will be required to define DA’s necessity and contribution to the functional plasticity of different striatal regions.

show abstract

Section: Dopamine System Genes and Neuropsychiatric Diseasementioning

confidence: 98%

Section: Dopamine System Genes and Neuropsychiatric Diseasementioning

confidence: 99%

Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease

Chen,

Kim

et al. 2021

Biomedicines

View full text Add to dashboard Cite

show abstract

“…This mutation has also been linked to reduced receptor density and function. Taq1A has been linked to a reduction in striatal D2 receptor binding (Ye et al 2019) A241G is associated with risperidone and olanzapine treatment response. Patients with the A allele had a stronger reaction to risperidone and have improved more, whereas G carriers have a slower response time (Ye et al 2019).…”

Section: Dopamine D2mentioning

confidence: 99%

Olanzapine Use in Schizophrenia and the Modulation of Its Response by Genetic Variations

2022

View full text Add to dashboard Cite

Schizophrenia is a chronic disease with diverse psychopathology and multiple phases of illness. Consequently, numerous factors must be considered when assessing the benefits of a given treatment over short- and long-term periods. Olanzapine is an atypical antipsychotic reported to be effective without producing many of the disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs. Despite the fact that olanzapine is still associated with a known risk of metabolic side effects, including weight gain, many clinicians continue to prescribe olanzapine for the treatment of schizophrenia with the expectation of additional therapeutic antipsychotic efficacy relative to other first-line atypical antipsychotics. This review focuses on the epidemiology, pathogenesis, and treatment of schizophrenia with special emphasis on the role of olanzapine in the treatment of schizophrenia. Genetic variants associated with the therapeutic efficacy and adverse effects of olanzapine are reviewed and those with the potential to act as a clinical predictor of therapeutic response and/or adverse effects are discussed. Recommendations are made for the use of some of these genetic variants in clinical medicine.

show abstract

“…Single-nucleotide polymorphism that exists also plays in clinical symptoms in patients (Vijayan et al, 2007). Single-nucleotide polymorphism (SNP) in DRD2 gene plays a role in therapeutic response and side efffects of therapy, including therapy with aripiprazole (Ye et al, 2019). ANKK1 gene in humans exists in chromosome 11.q22-23 and forms a cluster of NTAD (521 kilobase in length) (Mota et al, 2012;Ye et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

“…Single-nucleotide polymorphism (SNP) in DRD2 gene plays a role in therapeutic response and side efffects of therapy, including therapy with aripiprazole (Ye et al, 2019). ANKK1 gene in humans exists in chromosome 11.q22-23 and forms a cluster of NTAD (521 kilobase in length) (Mota et al, 2012;Ye et al, 2019). ANKK1 plays role in modulation of DRD2 activity (Mota et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Single Nucleotide Polymorphism rs1800497 in Risperidone and Aripiprazole Therapy for Schizophrenia Patients

Widodo

Saleh

Theodorus

2021

JPS

View full text Add to dashboard Cite

Schizophrenia is a variable of psychopathologic syndrome involving cognition, emotion, perception, and other behavioral aspects. Therapies on schizophrenia is solely based on history of mental illnesses and mental status. Schizophrenia affecting 1.1 million persons globally in 2017; 70.8% of them happened in 25-55 years old. This study was conducted in mental hospital in Palembang, Indonesia. Blood samples was taken from clinically diagnosed schizophrenia patients (20 patients taking aripiprazole and 60 patients taking risperidone) under therapy. DNA was extracted using Chelex 100 method and digested using Taq1 enzyme. DNA was electrophoresized and visualized. CC allele was found in 10% of patients taking aripiprazole and 11.67% patients taking risperidone. CT allele was found in 70% patients taking aripiprazole and 76.67% patients taking risperidone. TT allele was found in 20% patients taking aripiprazole and 11.67% patients taking risperidone. ANKK1 Taq1A polymorphism in schizophrenia patients shows different therapeutic response with worse therapeutic response compared to patients with normal allele.

show abstract

Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment

Cited by 9 publications

References 111 publications

Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease

Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease

Olanzapine Use in Schizophrenia and the Modulation of Its Response by Genetic Variations

Single Nucleotide Polymorphism rs1800497 in Risperidone and Aripiprazole Therapy for Schizophrenia Patients

Contact Info

Product

Resources

About